Mendus is a clinical stage immuno-oncology company based in Sweden and the Netherlands. It is focused on developing active immunotherapies that aim to improve long-term outcomes for patients with cancer, particularly in myeloid blood cancers where there remains significant unmet need. Its lead candidate, vididencel, is an off-the-shelf cellular immunotherapy designed to stimulate the patient’s own immune system against residual cancer cells. Mendus is developing vididencel across a broader acute myeloid leukaemia (AML) opportunity, covering both chemo-eligible and chemo-ineligible patient settings, while also expanding into chronic myeloid leukaemia (CML), where the goal is to support treatment-free remission.
There are four key reasons why Mendus may be considered a compelling investment opportunity:
1. Vididencel is supported by encouraging long-term clinical data in AML.
AML is an aggressive blood cancer associated with high relapse rates after initial treatment, often due to residual cancer cells that remain after remission. Vididencel is designed to address this challenge by helping the immune system recognise and control residual disease over time. The strongest clinical support to-date comes from the Phase II ADVANCE II study in AML maintenance. At the latest follow-up, 13 of 20 patients were still alive after a median follow-up of 55 months, with median relapse-free survival and overall survival not yet reached. Estimated five-year overall survival stood at 63%, which compares favourably with historical outcomes for available treatments in this setting. Importantly, immune responses induced by vididencel have also tracked with improved survival, supporting the proposed mechanism of action and strengthening the clinical rationale for further development.
2. Mendus’s clinical development strategy significantly broadens the AML opportunity.
The focus of the ADVANCE II proof-of-concept trial was on AML patients fit enough to receive intensive chemotherapy. This remains a key opportunity, with vididencel now being evaluated in the Phase IIb CADENCE trial in combination with oral azacitidine, the standard of care in AML maintenance. The development strategy expands this opportunity into chemo-ineligible patients through the planned Phase Ib DIVA trial, which will assess vididencel in combination with venetoclax plus azacitidine, a treatment regimen that has become increasingly important in first-line AML. This is an important strategic step because chemo-ineligible patients represent a substantial share of the AML population, and because the wider AML treatment landscape is moving towards the venetoclax plus azacitidine combination. By aligning vididencel with this evolving standard of care, Mendus is aiming to position the candidate across the two main treatment pathways following an AML diagnosis.
3. Expansion into CML provides a new and potentially sizeable opportunity.
Mendus has also moved vididencel into CML, a distinct blood cancer where tyrosine kinase inhibitors (TKIs) have transformed outcomes, but often require patients to remain on long-term therapy. This can create quality-of-life burdens and cumulative toxicity, making treatment-free remission (TFR), where patients remain in remission after stopping TKI therapy, an important goal in the field. The Phase I VITAL-CML trial has now commenced and will initially assess vididencel in patients with suboptimal responses to TKIs. The aim is to explore whether vididencel can strengthen immune control over residual disease and improve the likelihood of treatment discontinuation. Subject to supportive initial data, Mendus plans to move forward with VITAL-TFR2, a Phase II study in patients who have previously failed a TFR attempt. This expansion adds an opportunity to the investment case, and could materially broaden vididencel’s long-term commercial potential.
4. Multiple upcoming clinical catalysts may shape the next stage of development.
Mendus is entering a period of potentially important clinical newsflow. In AML, CADENCE is expected to provide early data that will inform the use of vididencel in combination with oral azacitidine, while DIVA is expected to test the candidate in the chemo-ineligible setting alongside venetoclax plus azacitidine. Together, these studies are expected to guide Mendus’s go-to-market strategy in AML, and may support progression towards a registrational trial. In CML, the first interim readout from VITAL-CML is expected to provide initial safety and early molecular efficacy data. If supportive, this could enable the launch of the planned VITAL-TFR2 study, allowing the company to run complementary CML studies in parallel. These milestones provide a series of near-term inflection points that could clarify vididencel’s role across myeloid blood cancers, and support future partnering discussions.
In summary, Mendus presents a focused investment case centred on vididencel, supported by encouraging AML data, a broader clinical strategy, expansion into CML and multiple upcoming catalysts. For more information on Mendus, please visit the Edison website.
Published 03 July 2026
